Sirtex FY12 profit grows nearly 50%
29 August, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) increased its FY12 profit by 49%, on the back of strong sales of its SIR-Spheres targeted radiation therapy treatments for liver cancer.
Quarterly payments for R&D Tax Incentive progress to consultation
28 August, 2012 by AusBiotechPlans are now progressing for the implementation of quarterly payments of the R&D Tax Incentive, to be accessible for each quarter commencing on or after 1 January 2014. In preparations, the Assistant Treasurer, the Hon David Bradbury and the Minister for Industry and Innovation, the Hon Greg Combet, have jointly released a public consultation paper on the design and implementation of the R&D quarterly credits.
Nanosonics triples revenue from Trophon EPR sales
27 August, 2012 by Dylan Bushell-EmblingStrong early sales of Nanosonics' (ASX:NAN) disinfection cabinets helped the company triple its revenue and cut its full-year losses by 58% in FY12.
MiReven gets extra $500k for microRNA cancer research
27 August, 2012 by Dylan Bushell-EmblingStart-up MiReven has received a $500,000 funding injection, after forging R&D partnerships and reaching internal milestones in efforts to develop cancer treatments based on a strain of microRNA.
Trial of NovoSorb hit with delays: Calzada
24 August, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) has been forced to push back the planned completion date for a planned human clinical trial of its NovoSorb BTM burns treatment product until well into 2013.
Court calls meeting to vote on Alchemia spinoff
24 August, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has reached two new milestones in its efforts to spin off its oncology business into a separate company listed on the Nasdaq.
Patrys raises cash, shaves loss in FY12
23 August, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) ended FY12 in a more stable financial position, after raising enough cash to see it through until early 2014.
Business Tax Working Group discusses cuts to R&D Tax Incentive
23 August, 2012 by AusBiotechAusBiotech invites members’ comments on the recently released Business Tax Working Group (BTWG) discussion paper, which includes amongst its issues for discussion four options that seek to limit the R&D Tax Incentive to companies with turnover over $20 million.
GI Dynamics gets FDA provisional nod for pivotal EndoBarrier trial
23 August, 2012 by Dylan Bushell-EmblingThe US FDA has provisionally cleared GI Dynamics (ASX:GID) to jump straight to a full clinical trial of EndoBarrier to treat Type 2 diabetes patients who are obese.
Mesoblast stem cell R&D spend triples
22 August, 2012 by Tim DeanMesoblast (ASX:MSB) has reinvested a sizeable chunk of the revenues from its licensing deal with Cephalon into boosting research and development efforts for its adult stem cell technology, bumping up total expenses by more than $58 million in FY12.
Oncology start-up Senz gets seed funding for chemo agent
22 August, 2012 by Dylan Bushell-EmblingStart-up Senz Oncology has secured seed funding to support the development of a chemotherapeutic agent as a potential treatment for acute leukaemias.
CSL lifts FY12 profit to US$1 billion
22 August, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) grew its FY12 net profit 4.5% to $983 million, despite taking a significant hit on exchange rates.
BioDiem viral vector research clears first hurdle
21 August, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and French partner VIVALIS have reached two significant milestones in their work towards the development of a new viral vector.
PM’s Manufacturing Taskforce reports
21 August, 2012 by AusBiotechNon-government members of the Prime Minister's Manufacturing Taskforce, representing business, unions and the research sector, have released their report Smarter Manufacturing for a Smarter Australia, after the group was established in late 2011.
Bioniche launching more animal health products
21 August, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched an equine inflammation treatment in the US, and scored Canadian distribution rights for six more products.
